Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
British Journal of Clinical Pharmacology|June 23, 2016
Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategyMahesh N Samtani, Partha Nandy, Paulien Ravenstijn, et al.
The Journal of Clinical Psychiatry|May 16, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)Dong-Jing Fu, Dawn F Ionescu, Xiang Li, et al.
Journal of Clinical Pharmacology|March 29, 2014
A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophreniaAdriaan Cleton, Stefaan Rossenu, Herta Crauwels, et al.
Annals of General Psychiatry|November 6, 2023
Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorderDavid Hough, Alice R Mao, Michael Aman, et al.
The International Journal of Neuropsychopharmacology|August 30, 2020
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)Dawn F Ionescu, Dong-Jing Fu, Xin Qiu, et al.
World Journal of Gastroenterology|February 21, 2017
Assessment of multi-modality evaluations of obscure gastrointestinal bleedingRyan Law, Jithinraj E Varayil, Louis M WongKeeSong, et al.
Current Medical Research and Opinion|June 7, 2016
Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophreniaPhillip Pierce, Srihari Gopal, Adam Savitz, et al.
The American Journal of Psychiatry|April 17, 2018
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Radiology|October 21, 2010
Appropriate patient selection at abdominal dual-energy CT using 80 kV: relationship between patient size, image noise, and image qualityLuís S Guimarães, Joel G Fletcher, William S Harmsen, et al.
Pageof 8